^
    Contact us  to learn more about
    our Premium Content:  News alerts, weekly reports and conference planners
    DRUG:

    Epidiolex (cannabidiol)

    i
    Other names: JZP926, JZP-926, GWP42003, GW-42003, GWP-42003-P, GWP-42003, CBD-OS
    Associations

    News

    Trials
    Company:
    Jazz
    Drug class:
    Cannabinoid receptor agonist
    Related drugs:
    Associations

    News

    Trials
    6d
    EpiTALY: Epidyolex® in Lennox Gastaut, Dravet Syndrome and Tuberous Sclerosis Complex: an Observational Study in ITALY (clinicaltrials.gov)
    P=N/A, N=100, Recruiting, Jazz Pharmaceuticals | Trial completion date: Jan 2026 --> Feb 2027 | Trial primary completion date: Jan 2026 --> Feb 2027
    Trial completion date • Trial primary completion date
    |
    Epidiolex (cannabidiol)
    9d
    Epidiolex in Obsessive Compulsive Disorder and Related Disorders (clinicaltrials.gov)
    P2, N=4, Completed, University of Chicago | Active, not recruiting --> Completed
    Trial completion
    |
    Epidiolex (cannabidiol)
    10d
    DEMURE: Dronabinol and Epidiolex to Manage Uncontrolled Residual Symptoms of Buprenorphine Initiation Trial (clinicaltrials.gov)
    P3, N=40, Not yet recruiting, Montefiore Medical Center | Trial completion date: Aug 2027 --> Dec 2027 | Initiation date: Jan 2026 --> May 2026 | Trial primary completion date: Aug 2027 --> Dec 2027
    Trial completion date • Trial initiation date • Trial primary completion date
    |
    Epidiolex (cannabidiol) • dronabinol oral
    1m
    NCI-2022-02479: Topical Cannabidiol for the Treatment of Chemotherapy-Induced Peripheral Neuropathy (clinicaltrials.gov)
    P2, N=40, Completed, Mayo Clinic | N=30 --> 40
    Enrollment change
    |
    Epidiolex (cannabidiol)
    2ms
    SCANS: Study of Cannabidiol and Neuroimaging on Stress (clinicaltrials.gov)
    P1/2, N=160, Recruiting, Icahn School of Medicine at Mount Sinai
    New P1/2 trial
    |
    Epidiolex (cannabidiol)
    3ms
    A Study to Evaluate the Efficacy and Safety of Cannabidiol Oral Solution (CBD-OS [GWP42003-P, JZP926]) for the Treatment of Focal-Onset Seizures (clinicaltrials.gov)
    P1, N=100, Recruiting, Jazz Pharmaceuticals | Not yet recruiting --> Recruiting
    Enrollment open
    |
    Epidiolex (cannabidiol)
    3ms
    A Phase 1b, Multicenter, Open-Label Study to Evaluate the Efficacy and Safety of Cannabidiol Oral Solution (CBD-OS [GWP42003-P, JZP926]) for the Treatment of Focal-Onset Seizures (clinicaltrials.gov)
    P1, N=100, Not yet recruiting, Jazz Pharmaceuticals
    New P1 trial
    |
    Epidiolex (cannabidiol)
    4ms
    A pilot randomised controlled trial testing the efficacy of cannabidiol for anxiety in Tourette Syndrome (ACTRN12621001659897)
    P3, N=20, Completed, Children's Health Queensland Hospital and Health Service | Not yet recruiting --> Completed | N=40 --> 20
    Trial completion • Enrollment change
    |
    Epidiolex (cannabidiol)
    5ms
    DEMURE: Dronabinol and Epidiolex to Manage Uncontrolled Residual Symptoms of Buprenorphine Initiation Trial (clinicaltrials.gov)
    P3, N=40, Not yet recruiting, Montefiore Medical Center | Trial completion date: Apr 2027 --> Aug 2027 | Initiation date: Sep 2025 --> Jan 2026 | Trial primary completion date: Apr 2027 --> Aug 2027
    Trial completion date • Trial initiation date • Trial primary completion date
    |
    Epidiolex (cannabidiol) • dronabinol oral
    5ms
    Drug-gene-nutraceutical Interactions of Cannabidiol and Tacrolimus (clinicaltrials.gov)
    P1, N=57, Completed, Indiana University | Recruiting --> Completed | Trial completion date: Oct 2028 --> Aug 2025 | Trial primary completion date: Oct 2028 --> Aug 2025
    Trial completion • Trial completion date • Trial primary completion date
    |
    Epidiolex (cannabidiol)
    6ms
    Role of CBD in Regulating Meal Time Anxiety in Anorexia Nervosa (clinicaltrials.gov)
    P1, N=40, Active, not recruiting, University of California, San Diego | Trial completion date: Nov 2025 --> Jun 2026 | Trial primary completion date: Nov 2025 --> Jun 2026
    Trial completion date • Trial primary completion date
    |
    Epidiolex (cannabidiol)
    6ms
    CREWS: Effects of Cannabidiol on Stress and Nicotine Withdrawal (clinicaltrials.gov)
    P1, N=90, Recruiting, Johns Hopkins University | Not yet recruiting --> Recruiting
    Enrollment open
    |
    Epidiolex (cannabidiol)